Pyridostigmine
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Pyridostigmine: Autoimmune disease of peripheral nervous system
One-Sentence Summary
Pyridostigmine is a cholinesterase inhibitor originally used to treat myasthenia gravis and related neuromuscular junction disorders. Support currently comes from 3 publications (a review, a case report and a cohort study) and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Autoimmune disease of peripheral nervous system |
| TxGNN Prediction Score | 0.9975 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (12 of 12) – CDSCO approval status is not included in this data |
| Number of Listed Products | 12 (valid: 12) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Pyridostigmine is a reversible acetylcholinesterase inhibitor. By slowing acetylcholine breakdown, it increases acetylcholine at the neuromuscular junction and improves muscle strength. Detailed mechanism-of-action data were not available in the data compiled for this report, but this symptomatic mechanism is well established for the drug.
Thymic hyperplasia is common in acetylcholine receptor (AChR) antibody-positive myasthenia gravis. The predicted indication is therefore essentially a subtype of the approved indication rather than a true repurposing. The symptomatic benefit of cholinesterase inhibition does not depend on thymic pathology.
They are listed in the next-steps section. Two predictions, hypersplenism and atypical haemolytic-uraemic syndrome with factor B anomaly, have no mechanistic rationale and no supporting studies.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34225443 | 2021 | Review | Molecular Medicine Reports | Genomic, phenotypic and epigenetic review of myasthenia gravis pathology and autoimmunity |
| 25683765 | 2015 | Cohort | Journal of Neurology | Two-year outcomes of thymectomy in 39 patients with non-thymomatous late-onset myasthenia gravis |
| 18053719 | 2008 | Case report | Neuromuscular Disorders | MuSK-positive myasthenia gravis with thymus hyperplasia presenting with dropped head syndrome |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 136415 | Mygris 60mg Tablet | Strip of 10 tablets | Not stated in the records |
| 94756 | Gravitor SR Tablet | Strip of 10 SR tablets | Not stated in the records |
| 134082 | Myestin 60mg Tablet | Strip of 10 tablets | Not stated in the records |
| 178890 | Pyristig 60mg Tablet | Strip of 10 tablets | Not stated in the records |
| 181021 | Pyrido 60mg Tablet | Strip of 10 tablets | Not stated in the records |
All 12 registrations are valid single-ingredient oral products, and none has been cancelled.
Safety Considerations
- Contraindications flagged in the knowledge graph (drug-disease associations, not package insert text): kidney disease, pyoureter, asthma (including intrinsic and allergic asthma), and urinary tract obstruction.
- Drug Interactions: 78 interactions were recorded. The 20 reviewed are all of moderate severity. They fall mainly into these groups:
- Anticholinergic agents (atropine, scopolamine, hyoscyamine, glycopyrronium, dicyclomine, trospium, propantheline, clidinium, methscopolamine, mepenzolate), which may oppose the effect of pyridostigmine.
- Corticosteroids (hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, budesonide, triamcinolone).
- Aminoglycosides (neomycin, kanamycin, paromomycin).
Warnings and contraindications from the package insert were not available. Please refer to the package insert for complete safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Pyridostigmine is already marketed in India for myasthenia gravis, and thymic hyperplasia is a common feature of AChR-positive disease, so the predicted indication largely overlaps with established use. Evidence is limited to a review, a case report and a cohort study, with no registered trials specific to this subtype.
To proceed, the following is needed:
- Package insert warnings and contraindications for the Indian products, which are currently missing.
- Detailed mechanism-of-action data.
- Confirmation that the approved indication wording covers myasthenia gravis subtypes, since the records contain no indication text.
- Subtype-level review of the other predictions:
- Neonatal myasthenia gravis: neonatal dosing and safety data are needed.
- Autoimmune peripheral nervous system disease: cholinesterase inhibitors can worsen some congenital myasthenic subtypes, so each subtype needs its own assessment.
- Autoimmune limb-girdle myasthenia: only a single case report supports it.
- MuSK-positive myasthenia gravis: response to cholinesterase inhibitors is variable.
- Hypersplenism and atypical haemolytic-uraemic syndrome should stay on hold unless a mechanistic hypothesis is developed.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.